Prospective Study
Copyright ©The Author(s) 2021.
World J Clin Cases. Dec 6, 2021; 9(34): 10595-10603
Published online Dec 6, 2021. doi: 10.12998/wjcc.v9.i34.10595
Table 2 Comparison of the hemodynamic parameter between the two groups (mean ± SD)
Indicators
T0
T1
T2
T3
HR (times/min)
Remimazolam group (n = 40)76.7 ± 7.168.3 ± 6.566.8 ± 5.978.8 ± 6.6
Propofol group (n = 40)78.2 ± 7.766.7 ± 6.765.1 ± 6.080.5 ± 7.3
t value-0.906 1.091 1.278 -1.093
P value0.368 0.279 0.205 0.278
MAP (mmHg)
Remimazolam group (n = 40)98.4 ± 5.388.3 ± 4.786.7 ± 4.2102.1 ± 4.8
Propofol group (n = 40)99.6 ± 4.786.0 ± 4.483.8 ± 4.5103.8 ± 4.2
t value-1.071 2.259 2.980 -1.686
P value0.287 0.027 0.004 0.096
CI (L/min·m2)
Remimazolam group (n = 40)3.67 ± 0.623.52 ± 0.523.58 ± 0.483.57 ± 0.53
Propofol group (n = 40)3.80 ± 0.603.40 ± 0.483.51 ± 0.503.65 ± 0.49
t value-0.953 1.072 0.639 -0.701
P value0.344 0.287 0.525 0.485
SVI (mL/m2·bpm)
Remimazolam group (n = 40)47.83 ± 5.8143.80 ± 5.2641.94 ± 5.5745.80 ± 5.16
Propofol group (n = 40)49.20 ± 5.6340.38 ± 4.9538.53 ± 4.8643.73 ± 5.57
t value-1.071 2.995 2.918 1.724
P value0.287 0.004 0.005 0.089